Targeting Angiogenic Pathways and Combination Approaches

Dear Colleagues,

Targeting of the tumor vasculature is attracting renewed attention because of the observed benefit of this therapeutic strategy in combination therapies. A great example is the enhanced efficacy of immunotherapy in combination with angiogenesis inhibitors. This is best observed in, but not limited to, checkpoint inhibition therapy. Thus, the continued development of anti-angiogenic strategies, as well as identification of attractive targets in the tumor vasculature, is critical. Additionally, when these strategies are used alongside other cancer therapies, synergism with anti-angiogenic approaches is seen, such as in chemo- and radiation therapy, as well as in hyperthermia and photodynamic therapy. 

In recent years, it has been demonstrated that anti-angiogenic therapy is beneficial when administered in combination with other therapies. Many strategies targeting the tumor vasculature have been developed, though they have received less attention because of the limited efficacy of anti-angiogenic drugs in cancer patients. This emphasizes the importance of targeting the tumor vasculature.

We are pleased to announce a Special Issue for Cancers entitled ‘Targeting Angiogenic Pathways and Combination Approaches’. The aim of this Special Issue is to draw attention to vascular targeting approaches and increase knowledge on the combination of this strategy with other cancer therapies, such as immune-, chemo-, radio- and photodynamic therapies.

The Special Issue aims to publish a collection of original research articles and reviews. Potential topics may include (but are not limited to):

• New strategies for targeting the tumor vasculature.
• Combination strategies of anti-angiogenic therapy and other anti-cancer approaches.
• Enhanced insight in the mechanisms of angiogenesis and anti-angiogenesis.
• In vitro, preclinical and clinical approaches of anti-angiogenesis and combination therapies.

We look forward to receiving your contributions.

Prof. Dr. Patrycja Nowak-Sliwinska
Prof. Dr. Arjan Griffioen
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• vascular targeting
• anti-angiogenic therapy
• combination therapy
• targeted therapy
• immunotherapy